文献速递淋巴瘤

维奈克拉联合剂量调整的R-EPOCH方案治疗Richter综合征

Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
PubMed 文献 · Blood · 2022-01-01

这项单臂、研究者发起的2期试验评估维奈克拉联合剂量调整的R-EPOCH方案(VR-EPOCH)治疗Richter综合征的完全缓解率。26例可评估患者中13例(50%)达到完全缓解,另3例达部分缓解,总缓解率62%。中位无进展生存期10.1个月,中位总生存期19.6个月;常见≥3级血液学毒性为中性粒细胞减少(65%)和血小板减少(50%),发热性中性粒细胞减少发生率为38%。

要点

  • VR-EPOCH方案在Richter综合征中完全缓解率为50%(13/26),总缓解率62%。
  • 中位无进展生存期10.1个月,中位总生存期19.6个月。
  • 每日加速维奈克拉剂量递增未观察到肿瘤溶解综合征。

核心结论

  • VR-EPOCH方案在Richter综合征中具有活性,与历史方案相比可获得更深、更持久的缓解。
  • 作者认为有必要开展比较维奈克拉联合化学免疫治疗与单用化学免疫治疗的研究。

研究设计与样本

  • 单臂、研究者发起的2期试验,评估维奈克拉联合剂量调整的R-EPOCH方案(VR-EPOCH)治疗Richter综合征的完全缓解率。
  • 患者先接受1个周期R-EPOCH,待血细胞计数恢复后,每日加速维奈克拉剂量递增至400 mg,随后接受VR-EPOCH最多5个21天周期。
  • 缓解者接受维奈克拉维持治疗或研究外细胞治疗。
  • 共26例患者接受治疗。
  • 试验注册号为NCT03054896。

主要发现

  • 26例患者中13例(50%)达到完全缓解,其中11例达到骨髓CLL微小残留病不可测。
  • 另3例达到部分缓解,总缓解率62%。
  • 中位无进展生存期为10.1个月,中位总生存期为19.6个月。
  • 血液学毒性包括≥3级中性粒细胞减少(65%)和血小板减少(50%),发热性中性粒细胞减少发生率为38%。
  • 每日维奈克拉剂量递增期间无患者发生肿瘤溶解综合征。

关键数值与推荐

  • 完全缓解率:50%(13/26)。
  • 中位无进展生存期:10.1个月。
  • 中位总生存期:19.6个月。
  • ≥3级中性粒细胞减少发生率65%,≥3级血小板减少发生率50%,发热性中性粒细胞减少发生率38%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 观察到强化化学免疫治疗和维奈克拉的毒性。
  • 作者认为有必要开展比较维奈克拉联合化学免疫治疗与单用化学免疫治疗的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Richter syndrome (RS) of chronic lymphocytic leukemia (CLL) is typically chemoresistant, with a poor prognosis. We hypothesized that the oral Bcl-2 inhibitor venetoclax could sensitize RS to chemoimmunotherapy and improve outcomes. We conducted a single-arm, investigator-sponsored, phase 2 trial of venetoclax plus dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (VR-EPOCH) to determine the rate of complete response (CR). Patients received R-EPOCH for 1 cycle, then after count recovery, accelerated daily venetoclax ramp-up to 400 mg, then VR-EPOCH for up to 5 more 21-day cycles. Responders received venetoclax maintenance or cellular therapy off-study. Twenty-six patients were treated, and 13 of 26 (50%) achieved CR, with 11 achieving undetectable bone marrow minimal residual disease for CLL. Three additional patients achieved partial response (overall response rate, 62%). Median progression-free survival was 10.1 months, and median overall survival was 19.6 months. Hematologic toxicity included grade ≥3 neutropenia (65%) and thrombocytopenia (50%), with febrile neutropenia in 38%. No patients experienced tumor lysis syndrome with daily venetoclax ramp-up. VR-EPOCH is active in RS, with deeper, more durable responses than historical regimens. Toxicities from intensive chemoimmunotherapy and venetoclax were observed. Our data suggest that studies comparing venetoclax with chemoimmunotherapy to chemoimmunotherapy alone are warranted. This trial was registered at www.clinicaltrials.gov as #NCT03054896.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Davids MS, Rogers KA, Tyekucheva S, et al. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood. 2022. PMID: 34788401. doi:10.1182/blood.2021011386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。